Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$26.15 - $37.26 $1,699 - $2,421
65 New
65 $4,000
Q2 2022

Aug 05, 2022

SELL
$36.01 - $74.24 $2,340 - $4,825
-65 Closed
0 $0
Q3 2021

Oct 05, 2021

BUY
$73.2 - $107.87 $4,758 - $7,011
65 New
65 $5,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.44B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Hanseatic Management Services Inc Portfolio

Follow Hanseatic Management Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hanseatic Management Services Inc with notifications on news.